These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 27246973)

  • 1. Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.
    Keppler S; Weiβbach S; Langer C; Knop S; Pischimarov J; Kull M; Stühmer T; Steinbrunn T; Bargou R; Einsele H; Rosenwald A; Leich E
    Oncotarget; 2016 Jun; 7(25):38762-38774. PubMed ID: 27246973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
    Hechtman JF; Zehir A; Yaeger R; Wang L; Middha S; Zheng T; Hyman DM; Solit D; Arcila ME; Borsu L; Shia J; Vakiani E; Saltz L; Ladanyi M
    Mol Cancer Res; 2016 Mar; 14(3):296-301. PubMed ID: 26660078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Tumor-specific Mutations in Receptor Tyrosine Kinase Subdomain IX Significantly Reduce Extracellular Signal-regulated Kinase Activity.
    Serizawa M; Kusuhara M; Ohnami S; Nagashima T; Shimoda Y; Ohshima K; Mochizuki T; Urakami K; Yamaguchi K
    Anticancer Res; 2016 Jun; 36(6):2733-44. PubMed ID: 27272783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.
    Weißbach S; Langer C; Puppe B; Nedeva T; Bach E; Kull M; Bargou R; Einsele H; Rosenwald A; Knop S; Leich E
    Br J Haematol; 2015 Apr; 169(1):57-70. PubMed ID: 25521164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RTK mutations and human syndromeswhen good receptors turn bad.
    Robertson SC; Tynan JA; Donoghue DJ
    Trends Genet; 2000 Jun; 16(6):265-71. PubMed ID: 10827454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer.
    Duplaquet L; Figeac M; Leprêtre F; Frandemiche C; Villenet C; Sebda S; Sarafan-Vasseur N; Bénozène M; Vinchent A; Goormachtigh G; Wicquart L; Rousseau N; Beaussire L; Truant S; Michel P; Sabourin JC; Galateau-Sallé F; Copin MC; Zalcman G; De Launoit Y; Fafeur V; Tulasne D
    Mol Cancer Ther; 2019 Jun; 18(6):1137-1148. PubMed ID: 30926633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.
    Tao Z; Liu J; Li T; Xu H; Chen K; Zhang J; Zhou H; Sun J; Han J; Guo Z; Yang H; Cao WM; Hu X
    Front Oncol; 2021; 11():741142. PubMed ID: 34650924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
    Zhu VW; Klempner SJ; Ou SI
    Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene.
    Mendes Oliveira D; Grillone K; Mignogna C; De Falco V; Laudanna C; Biamonte F; Locane R; Corcione F; Fabozzi M; Sacco R; Viglietto G; Malanga D; Rizzuto A
    J Exp Clin Cancer Res; 2018 Apr; 37(1):84. PubMed ID: 29665843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks.
    Wagner JP; Wolf-Yadlin A; Sevecka M; Grenier JK; Root DE; Lauffenburger DA; MacBeath G
    Sci Signal; 2013 Jul; 6(284):ra58. PubMed ID: 23861540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
    Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
    Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
    Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD
    Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.
    Rand V; Huang J; Stockwell T; Ferriera S; Buzko O; Levy S; Busam D; Li K; Edwards JB; Eberhart C; Murphy KM; Tsiamouri A; Beeson K; Simpson AJ; Venter JC; Riggins GJ; Strausberg RL
    Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14344-9. PubMed ID: 16186508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
    Nanri T; Matsuno N; Kawakita T; Suzushima H; Kawano F; Mitsuya H; Asou N
    Leukemia; 2005 Aug; 19(8):1361-6. PubMed ID: 15902284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
    Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
    Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
    Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.
    Kastenhuber ER; Huse JT; Berman SH; Pedraza A; Zhang J; Suehara Y; Viale A; Cavatore M; Heguy A; Szerlip N; Ladanyi M; Brennan CW
    Acta Neuropathol; 2014 May; 127(5):747-59. PubMed ID: 24292886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
    Terashima M; Togashi Y; Sato K; Mizuuchi H; Sakai K; Suda K; Nakamura Y; Banno E; Hayashi H; De Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K
    Clin Cancer Res; 2016 Jul; 22(14):3663-71. PubMed ID: 26826182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation.
    de Larrea CF; Navarro A; Tejero R; Tovar N; Díaz T; Cibeira MT; Rosiñol L; Ferrer G; Rovira M; Rozman M; Monzó M; Bladé J
    Clin Cancer Res; 2012 Jul; 18(13):3697-704. PubMed ID: 22539802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.